Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Norman Wolmark, MD
NSABP Foundation Inc
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cancer Care Specialists of Central Illinois
Decatur, Illinois, United States
- Crossroads Cancer Center
Effingham, Illinois, United States
- Cancer Care Specialists of Central Illinois-Swansea
Swansea, Illinois, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Stefanie Spielman Comprehensive Cancer Center
Columbus, Ohio, United States
- West Virginia University
Morgantown, West Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 May 2019
- Primary completion
- 30 Jun 2023
- Completion
- 30 Jun 2024
- Last update posted
- 2 Jun 2021
- Registered enrollment
- 29
- Registry id
- NCT04024800
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.